

# Anna S Berghoff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7548192/publications.pdf>

Version: 2024-02-01

25  
papers

1,111  
citations

759233

12  
h-index

839539

18  
g-index

25  
all docs

25  
docs citations

25  
times ranked

2264  
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. <i>JAMA Oncology</i> , 2022, 8, 106.	7.1	53
2	Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events â€” a retrospective cohort study. <i>European Journal of Cancer</i> , 2022, 165, 184-194.	2.8	29
3	SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.9	2
4	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	3.2	21
5	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	4.2	10
6	SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 909-914.	1.9	2
7	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
8	NIMG-09. DETECTION OF ASYMPTOMATIC MALIGNANT LESIONS BY [18F]FDG PET/MRI IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2021, 23, vi129-vi129.	1.2	0
9	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi124.	1.2	0
10	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	4.5	17
11	SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3554.	1.6	40
12	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198.	2.9	25
13	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
14	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647.	4.5	4
15	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.	4.5	4
16	SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i33-i33.	0.7	0
17	New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). <i>ESMO Open</i> , 2019, 4, e000629.	4.5	78
18	How I treat anaplastic glioma without 1p/19q codeletion. <i>ESMO Open</i> , 2019, 4, e000534.	4.5	3

#	ARTICLE	IF	CITATIONS
19	Awareness of predatory journals and open access among medical oncologists: results of an online survey. <i>ESMO Open</i> , 2019, 4, e000580.	4.5	15
20	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	1.2	1
21	IMMU-26. VISUALIZING TUMOR CELL - LYMPHOCYTE INTERACTIONS IN THE BRAIN METASTATIC CASCADE USING IN VIVO TWO PHOTON MICROSCOPY. <i>Neuro-Oncology</i> , 2018, 20, vi126-vi127.	1.2	0
22	CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. <i>Neuro-Oncology</i> , 2018, 20, vi59-vi59.	1.2	0
23	MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi155-vi155.	1.2	0
24	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	30.7	359
25	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmmunology</i> , 2016, 5, e1057388.	4.6	239